Results 51 to 60 of about 2,234,624 (258)

KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response

Cell Death and Disease, 2022
Oxaliplatin resistance is a major challenge in the treatment of colorectal cancer (CRC). Many molecular targeted drugs for refractory CRC have been developed to solve CRC drug resistance, but their effectiveness and roles in the progression of CRC and ...
Xiaohui Shen, Yuchen Zhang, Zhuoqing Xu, Han Gao, Wenqing Feng, Wenchang Li, Yiming Miao, Zifeng Xu, Yaping Zong, Jingkun Zhao, Aiguo Lu   +10 more
doaj   +1 more source

EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells

Oncotarget, 2017
Erythropoietin-producing hepatocellular receptor A2 (EphA2) is upregulated in gastric cancer tissues and cells, which is accompanied by epithelial-mesenchymal transition (EMT). The current study was designed to establish the oxaliplatin-resistant human gastric cancer cell line SGC-7901/L-OHP, to determine if EMT in these cells could be reversed, and to
Wen, Qiaocheng, Chen, Zihua, Chen, Zhikang, Chen, Jinxiang, Wang, Ran, Huang, Changhao, Yuan, Weijie   +6 more
openaire   +2 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1

International Journal of Oncology, 2023
DNA double‑strand break repair is critically involved in oxaliplatin resistance in pancreatic ductal adenocarcinoma (PDAC). Hepatocyte nuclear factor 1 homeobox A (HNF1A) has received increased attention regarding its role in cancer progression. The present study explored the role of HNF1A in oxaliplatin resistance in PDAC.
Xia, Renpeng, Hu, Chonghui, Ye, Yuancheng, Zhang, Xiang, Li, Tingting, He, Rihua, Zheng, Shangyou, Wen, Xiaofeng, Chen, Rufu   +8 more
openaire   +2 more sources

Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities

Cells, 2022
Colorectal cancer is the second most common cancer in women, the third in men, and an important cause of cancer-related mortality. Recurrence and the development of chemotherapy resistance are major hindrances for patients’ treatment.
Vanessa Rodríguez-Fanjul, Rosa Guerrero-López, Beatriz Fernández-Varas, Rosario Perona, Ana Sastre-Perona, Leandro Sastre   +5 more
doaj   +1 more source

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer

British Journal of Cancer, 2022
Abstract Background Colorectal cancer (CRC), the most common cancer type, causes high morbidity and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have short overall survival. Thus, identifying molecules involved in the development of oxaliplatin resistance is critical for designing ...
Chi-Che Hsieh, Sen-Huei Hsu, Chih-Yu Lin, Hung-Jiun Liaw, Ting-Wei Li, Kuan-Ying Jiang, Nai-Jung Chiang, Shang-Hung Chen, Bo-Wen Lin, Po-Chuan Chen, Ren-Hao Chan, Peng-Chan Lin, Yu-Min Yeh, Che-Hung Shen   +13 more
openaire   +2 more sources

LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5

Scientific Reports, 2022
A major reason for treatment failure of cancer is acquisition of drug resistance. The specific mechanisms underlying hepatocellular carcinoma (HCC) chemoresistance need to be fully elucidated.
Chongsheng Xia, Yurui Sun, Yang Li, Junli Ma, Jing Shi   +4 more
doaj   +1 more source

HOTAIR/miR-1277-5p/ZEB1 axis mediates hypoxia-induced oxaliplatin resistance via regulating epithelial-mesenchymal transition in colorectal cancer

Cell Death Discovery, 2022
The hypoxic microenvironment contributes to the chemoresistance of many malignant tumors including colorectal cancer (CRC). Accumulating studies have indicated that long non-coding RNAs (lncRNAs) play important roles in chemotherapy resistance.
Xingyue Weng, Hao Liu, Jian Ruan, Miaoyan Du, Lingjie Wang, Jiayan Mao, Ying Cai, Xuemei Lu, Wei Chen, Yaqing Huang, Xiao Zhi, Jianzhen Shan   +11 more
doaj   +1 more source

Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer

Biomedicines, 2022
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In this study, oxaliplatin-resistant (OR) colorectal cancer (CRC) cells of HCT116, HT29, SW480 and SW620 were established by gradually increasing the drug ...
Sun Young Park, Ye Seo Chung, So Yeon Park, So Hee Kim   +3 more
openaire   +3 more sources

Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells

Oncology Reports, 2011
In spite of an initially promising anti-tumor activity, oxaliplatin-based combinatorial treatments can eventually result in a tumor resistance response. In this study we aimed to understand the role of autophagy in HCC cell resistance to oxaliplatin and to discuss its potential therapeutic implication. We found
Hailei, Du, Weiping, Yang, Lin, Chen, Mingming, Shi, Varun, Seewoo, Jiayu, Wang, Andy, Lin, Zhuoran, Liu, Weihua, Qiu   +8 more
openaire   +3 more sources